Kate Secombe

• Appointments

  Date	Position	Institution name
  2014 - 2016	Technical Assistant	University of Adelaide

• Awards and Achievements

  Date	Type	Title	Institution Name	Country	Amount
  2021	Award	South Australian Young Achiever in STEM	Awards Australia	Australia	-
  2020	Award	Young Scientist, 70th Lindau Nobel Laureate Meeting	Australian Academy of Science	Australia	-
  2020	Fellowship	Adam J Berry Fellowship Awardee	Australian Academy of Science and National Insititutes of Health (USA)	United States	-
  2019	Award	Outstanding Community Presentation, RAHsearch Showcase	Royal Adelaide Hospital	Australia	-
  2019	Award	CSIRO ON Pitch Competition, 2nd place	CSIRO	Australia	-
  2019	Honour	Falling Walls Australia, 2nd place	Australian Academy of Science	Australia	-
  2018	Award	Hans-Jürgen and Maria Ohff Research Grant	University of Adelaide	Australia	-
  2017	Scholarship	Lions Medical Research Foundation Inc Scholarship	The University of Adelaide	-	-
  2017	Award	Lions Medical Research Foundation Inc Travel Grant	-	-	-
  2017	Scholarship	Research Training Program Stipend	University of Adelaide	Australia	-
  2014	Achievement	Highest Honours Grade	-	-	-
  2014	Achievement	Best Honours Poster Presentation	-	-	-
  2013	Award	Faculty of Sciences Outstanding Academic Achievement	-	-	-
  2012	Award	Faculty of Sciences Outstanding Academic Achievement	-	-	-

• Education

  Date	Institution name	Country	Title
  2017 - 2021	University of Adelaide	Australia	PhD in Medicine
  2014 - 2014	University of Adelaide	Australia	Bachelor of Health Sciences (Honours)
  2010 - 2014	University of Adelaide	Australia	Bachelor of Science (Biomedical Science)

• Journals

  Year	Citation
  2025	Tillett, B. J., Dwiyanto, J., Secombe, K. R., George, T., Zhang, V., Anderson, D., . . . Hamilton-Williams, E. E. (2025). SCFA biotherapy delays diabetes in humanized gnotobiotic mice by remodeling mucosal homeostasis and metabolome. Nature Communications, 16(1), 2893. DOI
  2024	Nguyen, T. P. M., Woods, S. L., Secombe, K. R., Tang, S., Elz, A. S., Ayton, S., . . . Bowen, J. M. (2024). Ferroptosis - a potential feature underlying neratinib-induced colonic epithelial injury. Cancer Chemotherapy and Pharmacology, 94(4), 493-505. DOI
  2024	Stringer, A. M., Hargreaves, B. M., Mendes, R. A., Blijlevens, N. M. A., Bruno, J. S., Joyce, P., . . . Wardill, H. R. (2024). Updated perspectives on the contribution of the microbiome to the pathogenesis of mucositis using the MASCC/ISOO framework. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 32(8), 558-1-558-15. DOI Scopus4
  2023	Al-Qadami, G., Bowen, J., Van Sebille, Y., Secombe, K., Dorraki, M., Verjans, J., . . . Le, H. (2023). Baseline gut microbiota composition is associated with oral mucositis and tumour recurrence in patients with head and neck cancer: a pilot study. Supportive Care in Cancer, 31(1), 98-1-98-14. DOI Scopus20 WoS5 Europe PMC17
  2023	Korver, S. K., Bowen, J. M., Gibson, R. J., Ball, I. A., Secombe, K. R., Wain, T. J., . . . Coller, J. K. (2023). Advanced statistics identifcation of participant and treatment predictors associated with severe adverse efects induced by fuoropyrimidine‑based chemotherapy. Cancer Chemother Pharmacol, 91(6), 507-521. DOI Scopus2 Europe PMC1
  2023	Hart, N. H., Wallen, M. P., Farley, M. J., Haywood, D., Boytar, A. N., Secombe, K., . . . Wardill, H. R. (2023). Exercise and the gut microbiome: implications for supportive care in cancer. Supportive Care in Cancer, 31(12), 724-1-724-24. DOI Scopus3 Europe PMC1
  2022	Secombe, K. R., Crame, E. E., Tam, S. Y. J., Wardill, H. R., Gibson, R. J., Coller, J. K., & Bowen, J. M. (2022). Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatment.. Cancer Chemother Pharmacol, 89(2), 275-281. DOI Scopus6 WoS3 Europe PMC6
  2022	Al-Qadami, G. H., Secombe, K. R., Subramaniam, C. B., Wardill, H. R., & Bowen, J. M. (2022). Gut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities. Microorganisms, 10(10), 2048. DOI Scopus71 WoS14 Europe PMC61
  2022	Secombe, K. R., Ball, I. A., Wignall, A. D., Bateman, E., Keefe, D. M., & Bowen, J. M. (2022). Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats. Neoplasia, 30, 100806-1-100806-10. DOI Scopus11 WoS4 Europe PMC11
  2021	Secombe, K. R., Al-Qadami, G. H., Subramaniam, C. B., Bowen, J. M., Scott, J., Van Sebille, Y. Z. A., . . . Wardill, H. R. (2021). Guidelines for reporting on animal fecal transplantation (GRAFT) studies: recommendations from a systematic review of murine transplantation protocols. Gut Microbes, 13(1), 1979878-1-1979878-15. DOI Scopus53 WoS26 Europe PMC38
  2021	Crame, E. E., Bowen, J. M., Secombe, K. R., Coller, J. K., François, M., Leifert, W., & Wardill, H. R. (2021). Epithelial-Specific TLR4 Knockout Challenges Current Evidence of TLR4 Homeostatic Control of Gut Permeability. Inflammatory Intestinal Diseases, 6(4), 1-11. DOI Scopus3 Europe PMC4
  2021	Secombe, K. R., Ball, I. A., Shirren, J., Wignall, A. D., Keefe, D. M., & Bowen, J. M. (2021). Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant.. Breast Cancer, 28(1), 99-109. DOI Scopus10 WoS3 Europe PMC6
  2020	Secombe, K. R., Van Sebille, Y. Z. A., Mayo, B. J., Coller, J. K., Gibson, R. J., & Bowen, J. M. (2020). Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome.. Integr Cancer Ther, 19, 1534735420928493. DOI Scopus49 WoS26 Europe PMC41
  2020	Mayo, B., Secombe, K., Wignall, A., Bateman, E., Thorpe, D., Pietra, C., . . . Bowen, J. (2020). The GLP-2 Analogue Elsiglutide Reduces Diarrhoea Caused by the Tyrosine Kinase Inhibitor Lapatinib in Rats. Cancer Chemotherapy and Pharmacology, 85(4), 793-803. DOI Scopus23 WoS12 Europe PMC16
  2019	Secombe, K. R., Coller, J. K., Gibson, R. J., Wardill, H. R., & Bowen, J. M. (2019). The bidirectional interaction of the gut microbiome and the innate immune system: Implications for chemotherapy‐induced gastrointestinal toxicity. International Journal of Cancer, 144(10), 2365-2376. DOI Scopus66 WoS39 Europe PMC44
  2019	Secombe, K., Ball, I., Shirren, J., Wignall, A., Finnie, J., Keefe, D., . . . Bowen, J. (2019). Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model. Cancer Chemotherapy and Pharmacology, 83(3), 531-543. DOI Scopus16 WoS8 Europe PMC10
  2019	Wardill, H., Secombe, K., Bryant, R., Hazenberg, M. D., & Costello, S. (2019). Adjunctive fecal microbiota transplantation in supportive oncology: emerging indications and considerations in immunocompromised patients. EBioMedicine, 44, 730-740. DOI Scopus56 WoS36 Europe PMC36
  2017	Coller, J. K., Bowen, J. M., Ball, I. A., Wardill, H. R., Van Sebille, Y. Z. A., Stansborough, R. L., . . . Gibson, R. J. (2017). Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. Cancer Chemotherapy and Pharmacology, 79(2), 431-434. DOI Scopus9 WoS7 Europe PMC6
  2017	Van Sebille, Y., Gibson, R., Wardill, H., Secombe, K., Ball, I., Keefe, D., . . . Bowen, J. (2017). Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats. International Journal of Cancer, 140(12), 2820-2829. DOI Scopus28 WoS22 Europe PMC23
  2016	Wardill, H., Gibson, R., Van Sebille, Y., Secombe, K., Logan, R., & Bowen, J. (2016). A novel in vitro platform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options. Experimental Biology and Medicine, 241(13), 1386-1394. DOI Scopus8 WoS7 Europe PMC6
  2016	Wardill, H., Gibson, R., Van Sebille, Y., Secombe, K., Coller, J., White, I., . . . Bowen, J. (2016). Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms. Molecular Cancer Therapeutics, 15(6), 1376-1386. DOI Scopus113 WoS82 Europe PMC78
  2016	Wardill, H., Bowen, J., Van Sebille, Y., Secombe, K., Coller, J., Ball, I., . . . Gibson, R. (2016). TLR4-dependent claudin-1 internalization and secretagogue-mediated chloride secretion regulate irinotecan-induced diarrhea. Molecular Cancer Therapeutics, 15(11), 2767-2779. DOI Scopus43 WoS33 Europe PMC20

• Conference Papers

  Year	Citation
  2021	Crame, E., Wardill, H. R., Secombe, K., Coller, J., & Bowen, J. (2021). Intestinal epithelial TLR4 are crucial to chemotherapy toxicity development. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 110). WILEY.
  2021	Secombe, K., Ball, I., Subramaniam, C., Al-Qadami, G., Bowen, J., & Wardill, H. R. (2021). Using patient-reported outcome measures to determine the role of the microbiome in cancer treatment-induced diarrhoea. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 174-175). WILEY.
  2021	Al-Qadami, G., Bowen, J., Van Sebille, Y., Wardill, H., Secombe, K., & Le, H. (2021). Pre-treatment gut microbiome and radiotherapy response and toxicities among patients with head and neck cancer. In MASCC/ISOO Annual Meeting.
  2019	Bowen, J. M., Secombe, K. R., Ball, I. A., Shirren, J., Wignall, A. D., Finnie, J. W., . . . Keefe, D. (2019). Budesonide and colesevelam reduce neratinib-induced diarrhea in a rat model. In CANCER RESEARCH Vol. 79 (pp. 2 pages). San Antonio, TX: AMER ASSOC CANCER RESEARCH. DOI
  2019	Bruning, E., Coller, J., Wardill, H., Secombe, K., & Bowen, J. (2019). Toll-like receptor 4 humanized C57BL/6 mouse intestinal permeability: A translational model for cancer treatment toxicity. In JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY Vol. 34 (pp. 166). WILEY.
  2019	Secombe, K., Bowen, J., Ball, I., Shirren, J., Wignall, A., Lalani, A., & Diala, I. (2019). The gut microbiome as an intervention target for neratinib-induced diarrhoea. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 15 (pp. 107-108). WILEY.
  2018	Wardill, H., Secombe, K., Gibson, R., Stringer, A., Al-Dasooqi, N., Mayo, B., & Bowen, J. (2018). Pre-treatment blautia abundance regulates chemo-toxicity in colorectal cancer patients: A pilot study. In NEUROGASTROENTEROLOGY AND MOTILITY Vol. 30 (pp. 1 page). WILEY.
  2018	Secombe, K., Bowen, J., Coller, J., Gibson, R., Stringer, A., Al-Dasooqi, N., . . . Wardill, H. R. (2018). Pre-treatment Blautia abundance regulates chemotherapy-induced gastrointestinal toxicity risk: a pilot study. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 14 (pp. 59). WILEY. WoS1

• Conference Items

  Year	Citation
  2021	Secombe, K. R., Ball, I. A., Wignall, A. D., Bateman, E., Diala, I., Lalani, A. S., & Bowen, J. M. (2021). Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats.. Poster session presented at the meeting of CANCER RESEARCH. Philadelphia, PA: AMER ASSOC CANCER RESEARCH.
  2017	Secombe, K. R., Ball, I. A., Shirren, J., Wignall, A. D., Wardill, H. R., Van Sebille, Y. Z. A., & Bowen, J. M. (2017). Budesonide Reduces Neratinib-Induced Gastrointestinal Injury and Diarrhoea in Rats. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. WoS2

• Datasets

  Year	Citation
  -	Secombe, K. (n.d.). GRAFT systematic review data. DOI

Practical Demonstrator

Physiology IIA and IIB

Human Anatomy and Physiology IB

Teaching Assistant

Precision Medicine

Guest Lecturer

Integrative Cell Biology

Biology of Disease II

Online Tutor

Foundations of Human Biology, University of South Australia

• Memberships

  Date	Role	Membership	Country
  2016 - ongoing	Member	Multinational Association for Supportive Care in Cancer	-
  2014 - ongoing	Member	Australian Society of Medical Research	-
  2013 - ongoing	Board Member	Faculty of Sciences Board	-
  2011 - ongoing	-	Golden Key International Honour Society	-

• Email: kate.secombe@adelaide.edu.au